Palvella Therapeutics (PVLA) director receives 3,000 stock options grant

Rhea-AI Filing Summary

Palvella Therapeutics director Elaine J. Heron received a grant of stock options for 3,000 shares of common stock. These options carry an exercise price of $102.19 per share and expire on June 10, 2036.

The options vest upon the earlier of the first anniversary of the June 10, 2026 grant date or the company’s next annual meeting of stockholders, subject to Heron’s continued service through the applicable vesting date. Following this grant, Heron holds 3,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider HERON ELAINE J

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	3,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 3,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 3,000 options Exercise price: $102.19 per share Expiration date: June 10, 2036 +2 more

5 metrics

Options granted 3,000 options Stock Option (Right to Buy) grant on June 10, 2026

Exercise price $102.19 per share Conversion or exercise price of granted options

Expiration date June 10, 2036 Option term end date

Underlying shares 3,000 shares Common stock underlying the options

Post-grant derivative holdings 3,000 options Total stock options held following the transaction

Key Terms

Stock Option (Right to Buy), exercise price, vesting, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "102.1900""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares subject to this option shall vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the Issuer's next annual meeting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"the date of the Issuer's next annual meeting of stockholders following the grant date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HERON ELAINE J

(Last) (First) (Middle)

C/O PALVELLA THERAPEUTICS, INC.

353 W. LANCASTER AVENUE, SUITE 200

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PALVELLA THERAPEUTICS, INC. [ PVLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$102.19	06/10/2026		A		3,000		(1)	06/10/2036	Common Stock	3,000	$0	3,000	D

Explanation of Responses:

1. The shares subject to this option shall vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the Issuer's next annual meeting of stockholders following the grant date, subject in each case to the Reporting Person's continued service through the applicable vesting date.

	/s/ Kathleen A. McGowan, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Palvella Therapeutics (PVLA) report for Elaine J. Heron?

Palvella Therapeutics reported that director Elaine J. Heron received a grant of stock options for 3,000 shares of common stock. These options were awarded as compensation, not purchased in the open market, and represent a new derivative position for Heron.

What is the exercise price of Elaine J. Heron’s Palvella (PVLA) stock options?

Elaine J. Heron’s stock options have an exercise price of $102.19 per share. This is the fixed price at which she may buy Palvella common stock if the options vest and are exercised before their expiration date.

When do Elaine J. Heron’s Palvella (PVLA) stock options vest?

The stock options vest on the earlier of the first anniversary of the June 10, 2026 grant date or the date of Palvella’s next annual stockholder meeting. Vesting also requires Heron to remain in service through the applicable vesting date.

When do the Palvella (PVLA) stock options granted to Elaine J. Heron expire?

The stock options granted to Elaine J. Heron expire on June 10, 2036. After that expiration date, any unexercised options will lapse and can no longer be used to purchase Palvella Therapeutics common stock at the $102.19 exercise price.

How many Palvella (PVLA) stock options does Elaine J. Heron hold after this filing?

Following this grant, Elaine J. Heron holds 3,000 stock options directly. Each option represents the right to purchase one share of Palvella Therapeutics common stock at the fixed exercise price of $102.19, subject to the vesting conditions described in the award.

Is Elaine J. Heron’s Palvella (PVLA) stock option grant an open-market purchase or compensation award?

Elaine J. Heron’s transaction is a compensation award, classified as a grant or other acquisition. The options were not bought in the open market; they were issued by Palvella as part of her service as a director, with vesting tied to continued service.